Human
melanoma Colo 679 cells were made resistant to
doxorubicin (
adriamycin, ADM) by continuous exposure to ascending concentrations of the drug and Colo/ADM80; a variant which grew continuously in the presence of 80 ng/ml of ADM was thus established. Human peripheral blood mononuclear cells (PBMC) produced
interferon gamma (IFN-gamma) when cultured with
mitomycin C (MMC)-treated parental Colo 679 cells. The synthesis of IFN-gamma was synergistically enhanced by adding
interleukin-18 (IL-18) and this was IL-12-dependent because a
neutralizing antibody against
IL-12 almost completely inhibited IFN-gamma production while control
antibodies (Abs) were inactive. The cellular sources of IFN-gamma were found to be B cells, CD8+ T cells and CD4+ T cells as revealed by flow cytometry after double staining for
surface antigens and staining for intracellular IFN-gamma. Interestingly, the resistant cell line induced much less IFN-gamma production than the parental cell line under the same co-culture conditions; however,
IL-18 could still enhance the production of IFN-gamma. In conclusion, our study shows that acquired resistance to anti-
cancer agents can also reduce immune responses to
cancer cells. However, the immunostimulatory
cytokine IL-18 could still enhance IFN-gamma production in drug resistant
tumor cell-PBMC cultures indicating that such immunostimulatory agents could still be beneficial in
immunotherapy for patients with recurrent drug resistant
tumors.